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KAJIAN FITOKIMIA LIPPIA NODIFLORA (L.) MICHX DAN 
AKTIVITI ANTI-HIPERURISEMIKNYA 
 
ABSTRAK 
 
Lippia nodiflora telah digunakan secara tradisional dalam Ayurveda, Unani, 
Sindh, dan Perubatan Tradisional Cina untuk rawatan sakit lutut sendi, lithiasis, 
diuresis, penyakit urinari dan bengkak. Dalam kajian ini, ekstrak metanol         
L. nodiflora menunjukkan aktiviti perencatan xantina oksidase (XOD) secara in vitro 
baik. Pemeringkatan berpandukan bioaktiviti ekstrak metanol menghasilkan empat 
pecahan (F1-F4) dengan F3 dikenal pasti sebagai pecahan yang paling poten. 
Penulenan F3 selanjutnya menghasilkan lima sebatian bioaktif, termasuk dua 
feniletanoid glikosida arenariosida (1) dan verbaskosida (2), dan tiga flavonoid 
6-hidroksiluteolin (3), 6-hidroksiluteolin-7-O-glikosida (4), dan nodifloretin (5), di 
mana 1 dan 4 diasingkan untuk kali pertama daripada L. nodiflora. Ekstrak metanol, 
pecahan-pecahan, dan juzuk kimia tersebut kemudiannya diuji untuk activiti 
antihiperurisemik berpotensi secara in vivo dengan menggunakan model tikus 
hiperurisemik diaruh oleh kalium oxonate dan hipoksantina. Rawatan oral ekstrak 
metanol menurunkan paras asid urik serum tikus hiperurisemik dengan berkesan dan 
bersandarkan dos. F3 menunjukkan kesan penurunan asid urik serum tikus yang 
tertinggi. Sebatian 3 merupakan sebatian yang paling poten antara sebatian-sebatian 
yang telah diasingkan di mana ia dapat menurunkan paras asid urik serum tikus 
hiperurisemik dengan signifikan dan bersandarkan dos. Namun begitu, 3 tidak 
 xxx
menurunkan paras asid urik serum tikus hiperurisemik rendah daripada kawalan 
normal walaupun pada dos tertinggi yang diberikan. Pemberian berulang F3 atau 3 
kepada tikus hiperurisemik selama 10 hari secara berterusan menyebabkan kesan 
penurunan asid urik serum yang signifikan dan progresif dalam tikus hiperusemik. 
Berbeza dengan allopurinol, ekstrak metanol dan F3 tidak menurunkan paras asid 
urik serum tikus normorurisemik. Tambahan pula, tiada kesan toksik diperhatikan 
dalam tikus-tikus yang diberi 5000 mg/kg ekstrak metanol atau F3, menunjukkan 
profil keselamatan mereka yang menggalakkan. Selepas itu, mekanisme aktiviti 
antihiperurisemik mereka ditafsirkan dengan menggunakan kajian in vivo perencatan 
XOD dan xantina dehidrogenase (XDH) hati tikus dan kajian urikosurik. Menariknya, 
3 berupaya untuk merencat aktiviti kedua-dua XOD dan XDH dalam hati tikus ke 
tahap yang setanding dengan allopurinol. Pengedokan molekul 3 mendedahkan 
bahawa 3 berinteraksi dengan XOD dengan susunan yang sama seperti allopurinol 
tetapi dengan tenaga pengikat bebas yang lebih rendah daripada allopurinol. Di 
samping itu, F4 meningkatkan penyingkiran asid urik tikus hiperurisemik secara 
signifikan. Sementara itu, satu kaedah kromatografi cecair berprestasi tinggi yang 
mudah dan boleh dipercayai dengan pengesanan ultralembayung telah dibangunkan 
dan disahkan untuk penentuan serentak lima sebatian bioaktif tersebut. Kaedah 
tersebut kemudiannya berjaya diaplikasikan untuk analisis fitokimia dan kajian 
farmakokinetik bagi 1-5 dalam sampel tumbuhan L. nodiflora dan sampel plasma 
tikus, masing-masing, untuk kali pertama. Batang kayu didapati memaparkan jumlah 
feniletanoid glikosida dan flavonoid yang tertinggi. Biokeperolehan oral untuk 
 xxxi
sebatian 1, 2, 3, 4, dan 5 didapati rendah dan tidak lengkap dengan anggaran nilai 
biokeperolehan oral mutlak 5.22, 2.10, 5.97, 3.13, dan 0.93 %, masing-masing. 
Diambil bersama, aplikasi berpotensi L. nodiflora terhadap hiperurisemia dalam tikus 
berdasarkan kegunaan tradisional telah ditunjukkan dalam kajian ini untuk kali 
pertama. Kesan antihiperurisemik yang dimiliki oleh L. nodiflora disumbangkan 
terutamanya oleh aktiviti perencatan XOD and XDH hati dan sebahagiannya oleh 
kesan urikosurik. Flavonoid adalah terutamanya bertanggungjawab untuk kesan 
penurunan asid urik oleh L. nodiflora dengan bertindak sebagai perencat XOD. 
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PHYTOCHEMICAL STUDIES OF LIPPIA NODIFLORA (L.) MICHX AND 
ITS ANTI-HYPERURICEMIC ACTIVITY 
 
ABSTRACT 
 
Lippia nodiflora has been traditionally used in the Ayurvedic, Unani, Sindh, 
and Traditional Chinese Medicine for the treatment of knee joint pain, lithiasis, 
diuresis, urinary disorder and swelling. In the present study, methanol extract of    
L. nodiflora showed promising xanthine oxidase (XOD) inhibitory activity in vitro. 
Bioactivity-guided fractionation of methanol extract yielded four fractions (F1-F4) 
with F3 being identified as the most potent fraction. Further purification of F3 
afforded five bioactive compounds, including two phenylethanoid glycosides 
arenarioside (1) and verbascoside (2), and three flavonoids 6-hydroxyluteolin (3), 
6-hydroxyluteolin-7-O-glycoside (4), and nodifloretin (5), of which 1 and 4 were 
first time isolated from L. nodiflora. The methanol extract, fractions, and chemical 
constituents were then tested for potential antihyperuricemic activity in vivo using 
potassium oxonate- and hypoxanthine-induced hyperuricemic rat model. Oral 
treatment with methanol extract effectively and dose-dependently reduced the serum 
uric acid level of hyperuricemic rats. F3 exhibited the highest rat serum uric acid 
lowering effect. Compound 3 was established as the most potent of the isolated 
chemical constituents whereby it significantly and dose-dependently reduced the 
serum uric acid level of hyperuricemic rats. Nonetheless, 3 did not lower the serum 
uric acid level of hyperuricemic rats below that of the normal control even at the 
 xxxiii
highest dose given. Repeated administration of F3 or 3 to the hyperuricemic rats for 
10 continuous days resulted in a significant and progressive serum uric acid lowering 
effect in hyperuricemic rats. In contrast to allopurinol, the methanol extract and F3 
did not reduce serum uric acid level of normoruricemic rats. Furthermore, no toxic 
effect was observed in rats administered with 5000 mg/kg of methanol extract or F3, 
indicating their favorable safety profile. Subsequently, their mechanism(s) of 
antihyperuricemic activity were elucidated using in vivo rat liver XOD and xanthine 
dehydrogenase (XDH) inhibitory and uricosuric studies. Interestingly, 3 was able to 
inhibit both XOD and XDH activities in rat liver to an extent comparable to the 
allopurinol. Molecular docking of 3 revealed that 3 interacted with XOD in a manner 
similar to allopurinol but with a free energy of binding lower than allopurinol. On the 
other hand, F4 significantly increased the uric acid excretion of hyperuricemic rats. 
Meanwhile, a simple and reliable high performance liquid chromatography with 
ultraviolet detection method was developed and validated for the simultaneous 
determination of the five bioactive compounds. The method was then successfully 
applied for the phytochemical analysis and pharmacokinetic study of 1-5 in L. 
nodiflora plant samples and rat plasma samples, respectively, for the first time. Stems 
were found to contain the highest total content of phenylethanoid glycosides and 
flavonoids. The oral bioavailability of the compound 1, 2, 3, 4, and 5 was found to be 
low and incomplete with estimated absolute oral bioavailability values of 5.22, 2.10, 
5.97, 3.13, and 0.93 %, respectively. Taken together, the potential application of         
L. nodiflora against hyperuricemia in rat in accordance with its traditional uses has 
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been demonstrated in the present study for the first time. The antihyperuricemic 
effect possessed by L. nodiflora was contributed mainly by liver XOD and XDH 
inhibitory activities and partially by uricosuric effect. Flavonoids are mainly 
accountable for the uric acid lowering effect of L. nodiflora by acting as XOD 
inhibitor. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Medicinal plants as potential source for drug discovery against 
 hyperuricemia  
A medicinal plant is defined by the World Health Organization (WHO) as a plant 
which is capable of inducing a pharmacological effect when it is applied in a 
particular form and by any means to the humans (Silva et al., 2011). Medicinal plants, 
particularly higher plants, once served as the main source of medicaments to 
humankind. Today, medicinal plants continue to retain their significance as 
important source of novel and known chemical constituents useful as medicinal 
agents and leads for the production of synthetic or semi-synthetic organic medicinal 
agents (Balandrin et al., 1993). 
 
 It has been reported that the medical indications of approximately 80 % of the 
plant-derived bioactive chemical constituents used as commercial drugs were the 
same or related to the traditional uses of their respective plants (Farnsworth et al., 
1985 cited in Fabricant and Farnsworth, 2001). For example, the plant Colchicum 
autumnale has been described in the Ebers Papyrus of 1500 B.C. and used to treat 
painful articular attacks and gouty arthritis. Of which its compound, colchicine found 
to exhibit activity reflecting the traditional uses of the plant and it is now a popular 
clinically used agent for hyperuricemia and gout therapy (Graham and Roberts, 
1953). 
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  The exploration and use of medicinal plants and their phytochemicals as 
potential antihyperuricemic agents dated back to thousand years ago since 
hyperuricemia-related diseases such as gout, osteoarthritis, rheumatism, bone and 
joint disorders, painful articular attacks, and joint pain are widely described in the 
ethnomedicine literature like Ayurveda (5000-3000 B.C.), Traditional Chinese 
Medicine (TCM, 2000 B.C.), and Ebers Papyrus (1500 B.C.) (Gourie-Devi et al., 
1991; Graham and Roberts, 1953; Lozano, 2014; Williamson, 2015).  
 
 To date, various medicinal plants and their phytochemicals have been 
reported to be active against hyperuricemia by inhibiting xanthine oxidase in vitro or 
in vivo. For medicinal plants, the examples include Larix laricina from northeastern 
North America (Owen and Johns, 1999), Clerodendrum floribundum, Eremophila 
maculata, and Stemodia grossa from Australia (Sweeney et al., 2001), Cinnamomum 
cassia, Chrysanthemum indicum, and Lycopus europaeus from China (Kong et al., 
2000), Strychnos nux-vomica, Coccinia grandis, and Vitex negundo from India 
(Umamaheswari et al., 2007), Averrhoa carambola, Carica papaya, Dimocarpus 
longan malesianus, Manikara zapota, and Salacca zalacca from Malaysia (Azmi et 
al., 2012). Whereas, the examples for phytochemicals include cinnamaldehyde 
isolated from Cinnamomum osmophloeum (Wang et al., 2008), iocineraflavone 
isolated from Lonicera hypoglauca (Chien et al., 2009), 4'-methylether 
robustaflavone, robustaflavone, eriodictyol, and amentoflavone isolated from 
Selaginella labordei (Tan et al., 2009), and riparsaponin isolated from Homonoia 
riparia (Xu et al., 2014). 
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 These examples clearly show that the search for new medicinal plants with 
antihyperuricemic activity and alternative uric acid lowering agents from medicinal 
plants are still ongoing. 
 
1.2 Lippia nodilflora 
Lippia nodiflora (L.) Michx, also known as Phyla nodiflora, is one of the medicinal 
plants recorded in the Ayurvedic, Unani, Sindh, and Traditional Chinese Medicine 
(TCM) systems (Khare, 2007; Umberto Quattrocchi, 2012; Yang et al., 2003). It has 
been extensively used as a traditional medicine to treat illness by the local 
community, has a very long history for human use, and has a broad array of reported 
pharmacological activities (Siddiqui et al., 2009). 
 
1.2.1 Taxonomy classification of Lippia nodiflora  
Kingdom: Plantae 
Division: Magnoliophyta 
Class:  Magnoliopsida 
Order:  Lamialas 
Family: Verbenaceae 
Genus:  Phyla 
Species: nodiflora 
(Adopted from Sharma and Singh, 2013) 
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Figure 1.1: Lippia nodiflora. 
 
1.2.2 Morphology of Lippia nodiflora 
Lippia nodiflora is a fast growing, creeping, prostate, much branched, and appressed 
medifixed hairs covered perennial herb (Figure 1.1) (Gadhvi et al., 2012; Munir, 
1993). It can grow up to a height of approximately 20-30 cm when in competition 
with other species (Sharma and Singh, 2013). The stems of the plant are 2-3 cm thick, 
30-95 cm long, and green to purple in color when young but becoming grey and 
woody with age (Leigh and Walton, 2004). The leaves are cuneate-spathulate to 
abovate in shape, 10-30 mm long, 5-12 mm wide, dentate at the upper margins, 
tapering gradually below to a short petiole or subsessile, with sharp antrorse teeth on 
the upper half, and usually arise in pairs in the opposite direction at the stem nodes 
(Leigh and Walton, 2004; Mandaville, 1990; Munir, 1993). Roots are fibrous, 
branched, brown in color, 2-10 cm in length, and 1-1.5 mm in diameter while nodal 
roots are smaller, 0.5-1 cm in length and unbranched (The Ayurvedic Pharmacopoeia 
of India, Volume V, Part I, 1989). The plant flowers are rose-purple to nearly white 
in color and produce in the spikes or heads on the slender auxiliary peduncles which 
are mostly 1.5-3.0 cm long (Foin and Unger, 1991; Munir, 1993).  
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1.2.3 Ethnobotanical uses of Lippia nodiflora 
The use of Lippia nodiflora as a folk medicine for treating various ailments has been 
recorded in medicinal systems and regions or countries as presented in Table 1.1. 
 
Table 1.1: Ethnobotanical uses of Lippia nodiflora. 
Medicinal system Ethnobotanical uses References  
Ayurveda, Unani, 
and 
Sindh 
 knee joint pain 
 urinary disorder 
 diuresis 
 burning sensation 
during urination 
 liver tonic 
 jaundice 
 gasointestinal disorders 
 skin disorders 
 atherosclerosis diseases 
 blood purification 
 pneumonia 
 blood dysentry 
 spasmolytic 
 cough 
 cold 
 headache 
 fever 
 indigestion 
 febrifuge 
 aphrodisiac 
 menstrual disorders 
 as a demulcent in cases 
of venereal diseases  
Khare, 2007 
Narendra et al., 2012 
Shanmugasundaram et al., 1983 
Umberto Quattrocchi, 2012 
   
Traditional 
Chinese Medicine 
(TCM) 
 removing wind, heat, 
and swelling 
 detoxicating 
 stranguria 
 sore throat 
 tonsillitis 
 suppurative infections 
on the body surface 
 dysentry of heat type 
 ulcerative gingivitis 
 herpes zoster 
Yang et al., 2003 
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Table 1.1: Continued. 
Region/ 
Country  
Ethnobotanical uses References  
United 
States of 
America  
 colds 
 grippe 
 bronchitis 
 coughs  
 asthma 
 orthopaedic aid 
Pascual et al., 2001 
Speck, 1941 in Austin, 2004 
   
Taiwan   treating inflammatory 
diseases like hepatitis 
and dermatitis 
 toxic 
 irregular menses 
 sore throat 
Li, 2006 
Yen et al., 2012 
   
Africa  malaria 
 arthritis 
 osteoarticular pains 
 diuresis 
 vermifuge 
 antiseptic 
 antitussive 
 respiratory diseases 
 bronchitis 
 dyspepsia 
 gonorrhoea 
 analgesic 
 inflammation 
 antipyretic 
 hookworm 
Forestieri et al., 1996 
Mukherjee, 1991 
Pascual et al., 2001 
   
India  spermatorrhoea 
 jaundice 
 diuresis 
 asthma 
 as 'laehiums' for 
paralysis 
 displacement of joint 
 cut wound and external 
wound 
 gastrointestinal problems 
Ambesta, 1986 in Nyman et al., 1998 
Chitravadivu et al., 2009 
Prusti and Behera, 2007 
Savithramma et al., 2007 
Muralidharan and Narasimhan, 2012 
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Table 1.1: Continued. 
Region/ 
Country 
Ethnobotanical uses References  
Pakistan  skin diseases 
 as cosmetic 
 micturition 
 dysuria 
 bleeding biles 
 indigestion in children 
 hepatitis 
 abscess 
 as cooling agent 
 as a demulcent in cases of 
venereal diseases  
 antidote for snake bite 
Abbasi et al., 2010 
Qureshi and Bhatti, 2008 
Khan et al., 2013 
Marwat et al., 2011 
   
Sindh  abscess 
 hepatitis 
 leishmaniasis 
 as an antidote to snake or 
scorpion sting 
Rahman et al., 2012 
   
Bangladesh  eczema 
 rheumatoid arthritis 
 nervous disorders 
 gonorrhoea 
 constipation 
 heat stroke 
 fever 
 spasms 
 headache 
 dizziness 
 pain in back or waist due 
to rheumatism 
 limb pain 
Rahmatullah et al., 2011 
Biswas et al., 2010 
   
Nepal  headache 
 fever 
 cough 
 cold 
Taylor, 1996 
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1.2.4 Phytochemicals of Lippia nodiflora 
Since 1959, over 50 chemical constituents have been isolated from L. nodiflora as 
listed in the Table 1.2. 
 
Table 1.2: Chemical constituents isolated from Lippia nodiflora. 
Class of 
compounds 
Name of chemical constituent References 
Flavonoids  nodifloretin (or 6-hydroxy-3'- 
methoxyluteolin or batatifolin) 
 
Barua et al., 1969 
Barua et al., 1971 
 6-hydroxyluteolin-7-O-apioside 
 luteolin-7-O-glucoside 
 
Barnabas et al., 1980 
 hispidulin-7-sulfate  
 hispidulin-7,4'-disulfate  
 jaceosidin-7,4'-disulfate  
 nepetin-3',4'-disulfate  
 nodifloretin-6,7-disulfate  
 6-hydroxyluteolin-6,7-disulfate  
 nodifloretin-7-sulfate  
 6-hydroxy-luteolin-6-sulfate  
 6-hydroxyluteolin-7-sulfate  
 jaceosidin-7-sulfate  
 nepetin-7-sulfate  
 hispidulin-4'-sulfate  
 hispidulin  
 jaceosidin 
 
Tomás-Barberán et al., 1987 
 
 demethoxycentaureidin (or 
5,7,3'-trihydroxy-6,4'-dimethoxy 
flavone) 
 
Khalil et al., 1995 
 ganzalitosin I (or 5-hydroxy-
3',4’,7-trimethoxy flavones) 
Sudha and Srinivasan, 2014 
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Table 1.2: Continued. 
Class of 
compounds 
Name of chemical constituent References 
Flavonoids  3,7,4',5'-tetrahydroxy-3'- 
methoxyflavone  
 4'-hydroxywogonin  
 onopordin  
 cirsiliol  
 larycitrin  
 5,7,8,4'-tetrahydroxy-3'-
methoxyflavone 
 
Lin et al., 2014 
Phytosterol  β-sitosterol glucoside 
 stigmasterol glucoside 
 
Barua et al., 1969 
Barua et al., 1971 
 β-sitosterol  
 
Akhtar, 1993 
 4', 5'-
dimethoxybenzoloxystigmasterol  
 stigmasterol 
 
Siddiqui et al., 2009 
Triterpene  3β-19α-dihydroxy-urs-1,20-(30)-   
diene  
 ursolic acid  
 pomolic acid 
 
Akhtar, 1993 
 
 Lippiacin 
 
Siddiqui et al., 2007 
Quinol  halleridone (or benzofuranone 
renglyolone)  
 hallerone 
 
Ravikanth et al., 2000 
Iridoid  loganin 
 catalpol  
 
Akhtar, 1993 
Phenylethanoid 
glycosides 
 acteoside (or verbascoside or 
kusaginin or russetinol or 
stereospermin)  
 2'-O-acetylechinacoside  
Khalil et al., 1995 
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Table 1.2: Continued. 
Class of 
compounds 
Name of chemical constituent References 
Others   nodifloridin A  
 nodifloridin B 
 
Joshi and Bhakuni, 1959 
 nodiflorin A  
 nodiflorin B   
 
Joshi and Bhuwan, 1970 
  cornoside 
 
Rimpler and Sauerbier, 1986 
 
 α-ethyl-galactose   Akhtar, 1993 
 
 As shown in the Table 1.2, majority of the chemical constituents isolated 
from L. nodiflora belonged to the class of flavonoids. 
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1.2.5 Pharmacological properties of Lippia nodiflora 
Lippia nodiflora has been reported to be active against a wide array of biological 
activities as listed in the Table 1.3. 
 
Table 1.3: Reported pharmacological effects of Lippia nodiflora. 
Reported biological activities References 
 Analgesic  Forestieri et al., 1996 
  
 Angiotensin converting enzyme 
inhibitory 
Nyman et al., 1998 
  
 Antiatherosclerotic  Shanmugasundaram et al., 1983 
  
 Anticancer Vanajothi et al., 2012 
Sankaranarayanan et al., 2013 
  
 Antidiabetic  Balamurugan and Ignacimuthu, 2011 
Balamurugan et al., 2011 
  
 Antihepatotoxic Durairaj et al., 2008 
Sampathkumar et al., 2008 
Balamurugan et al., 2011 
Narendra et al., 2012 
Sudha et al., 2013 
Arumanayagam and Arunmani, 2015 
  
 Antihyperlipidemia Balamurugan and Ignacimuthu, 2011 
Balamurugan et al., 2011 
  
 Antihypertensive  Akhtar, 1993 
Gadhvi et al., 2012 
Gadhvi et al., 2015 
  
 Antiinflammatory  Forestieri et al., 1996 
Balakrishnan et al., 2010 
Jabeen et al., 2015 
Ahmed et al., 2004 
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Table 1.3: Continued. 
Reported biological activities References 
 Antimicrobial Durairaj et al., 2007 
Sivakumar, 2008 
Jeya and Veerapagu, 2011 
Ravikumar and Sudha, 2011 
Malathi et al., 2011 
Zare et al., 2012 
Priyadarshni et al., 2013 
Regupathi et al., 2014 
Priya and Ravindhran, 2015 
Taylor, 1996 
Balakrishna et al., 1996 
Hsueh et al., 2010 
Jeyachandran et al., 2010 
Patel et al., 2011 
Salve and Bhuktar, 2012 
Thamaraiselvi et al., 2013 
Ullah et al., 2013 
Jabeen et al., 2015 
Anitha et al., 2013 
Regupathi and Chitra, 2015 
Pirzada et al. 2005 
Manimegalai and Ambikapathy, 2012 
Wang and Huang, 2005 
Simonsen et al., 2001 
Kavitha et al., 2012 
Mako and Noor, 2006 
  
 Antioxidant  Ashokkumar et al., 2008 
Ashokkumar et al., 2009 
Durairaj et al., 2008 
Shukla et al., 2009b 
Lin et al., 2014 
  
 Antipyretic  Forestieri et al., 1996 
  
 Antiulcer  Sumalatha, 2012 
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Table 1.3: Continued. 
Reported biological activities References 
 Kidney disorders Dodoala et al., 2010 
Ashok kumar et al., 2008 
Shukla et al., 2009a 
Gadhvi et al., 2015 
  
 Larvicidal Sivakumar, 2008 
  
 Lipid peroxide scavenging Durairaj et al., 2007 
  
 Melanogenesis inhibitory  Yen et al., 2012 
  
 Neuropharmacological  Turaskar et al., 2011 
  
 Skin whitening  Ko et al., 2014 
 
 
 In addition to the activities listed, Dodoala et al. (2010) showed that              
L. nodiflora ethanol extract also exhibited antiurolithiatic effect. The extract 
significantly prevented the formation of the calcium oxonate stone dissolved the pre-
formed calcium oxolate stone in the kidney of rats induced with gentamycin and 
calculi producing diet. The antiurolithiatic activity of the extract was due to its ability 
to increase the urinary pH and excretion of the calcium and oxolate, and also to 
reduce the urine supersaturation with the calculogenic ions.  
 
 On the other hand, methanol extract of L. nodiflora whole plant was found to 
possess diuretic properties by significantly increasing the urine volume of the treated 
rats with enhanced excretion of the Na+, Ca2+, and Cl accompanied by the excretion 
of the K+ in a dose-dependent manner as demonstrated by Ashok kumar et al. (2008). 
Besides, Shukla et al. (2009a) showed that both methanol and aqueous extracts of 
aerial parts of L. nodiflora possess significant diuretic potential by increasing the 
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urine volume, urinary concentration of the Na+ and K+ ions in an in vivo Lipschitz rat 
model. 
 
 Recently, Gadhvi et al. (2015) reported that L. nodiflora methanol extract 
exhibited kidney protective effect in the deoxycarticosteroneacetate-induced 
hypertensive rats. It significantly improved the serum creatinine level of the treated 
rats and the histopathology studies on the rat renal tissues of the treated rats showed 
fewer inflammatory cells with architecture close to normal control. 
 
 The antiurolithiatic, diuretic, and kidney protective activities of L. nodiflora 
described above suggested that it may possess activity against hyperuricemia. 
 
1.3 Hyperuricemia 
Hyperuricemia is a symptom of abnormally high uric acid concentration in blood. It 
arises when the serum uric acid level is greater than 6.0 mg/dL (350 µmol/L) in 
women and 7.0 mg/dL (450 µmol/L) in men (Fam, 1990; Sachs et al., 2009). Uric 
acid is formed from the metabolism of purine nucleotides (Wright, 1995).  
 
1.3.1 Nucleotides and purine nucleotides 
A nucleotide is a compound that contains either a purine (purine nucleotide) or 
pyrimidine (pyrimidine nucleotide) base. Purine nucleotides serve as building blocks 
for deoxyribonucleic acid (DNA), ribonucleic acid (RNA), sources of energy, extra- 
and intra-cellular messengers, secondary messengers, allosteric enzyme effectors, 
neurotransmitters, antioxidants, and precursors of coenzymes (Baranowska-Bosiacka 
et al., 2004; Cannella and Mikuls, 2005; Halabe and Sperling, 1994). Purine 
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nucleotides can be synthesized de novo, or reconstructed from already existing free 
purine bases through the salvage pathway (Baranowska-Bosiacka et al., 2004). 
 
1.3.2 Purine metabolism: de novo synthesis and salvage pathways of purine 
 nucleotides 
The synthesis of purine nucleotides occurs mainly in the liver (Moriwaki, 2014) and 
requires a source of ribose-5-phosphate which is produced from the glucose-6-
phosphate via pentose phosphate pathway (also known as hexose monophosphate 
shunt and phosphogluconate pathway) (Cohen and Roth, 1953; Larrabee, 1989). 
Ribose-5-phosphate formed is then converted into 5-phosphoribosyl-1-
pyrophosphate (PRPP) by PRPP synthetase (Figure 1.2). PRPP is the starting 
substrate for both purine biosynthesis de novo and salvage pathways. In the presence 
of the second substrate, L-glutamine, de novo synthesis pathway uses PRPP to 
generate the first purine nucleotides called inosine monophosphate (IMP) and from 
IMP to the other purine nucleotides called adenosine monophosphate (AMP) and 
guanosine monophosphate (GMP) (Gilbert, 2000; Wyngaarden, 1974).  
 
 Whereas, the salvage pathway uses PRPP to react with the free purine bases 
derived either from the turnover of nucleotides or from the diet to reconstruct purine 
nucleotides by using two salvage enzymes which are known as hypoxanthine-
guanine phosphoribosyltransferase (HGPRT), to catalyze the formation of IMP and 
GMP, and adenine phosphoribosyltransferase (APRT), to catalyze the formation of 
AMP (Baranowska-Bosiacka et al., 2004). 
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 Catabolism of the IMP, AMP and GMP purine nucleotides leads to the 
production of purine nucleosides namely inosine, adenosine and guanosine, then to 
the formation of purine bases namely hypoxanthine, xanthine and guanine, and 
ultimately to the generation of uric acid through the activities of xanthine 
oxidoreductase (XOR) (Choi et al., 2005). 
 
Ribose-5-phosphate
PRPP + L-glutamine
IMP
AMP GMP
HGPRTAPRT InosineAdenosine Guanosine
Hypoxanthine
Xanthine
Guanine
uric acid
Adenine
+ PRPP + PRPP
Feedback InhibitionFeedback Inhibition
XOR
XOR
 
Figure 1.2: Purine biosynthesis de novo and salvage pathways (Choi et al., 2005). 
 
1.3.3 Xanthine oxidoreductase 
Xanthine oxidoreductase (XOR), a rate-limiting enzyme in purine biosynthesis, 
exists in two forms as xanthine dehydrogenase (XDH), which is the primary gene 
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product of XOR and as xanthine oxidase (XOD), which is formed via the post-
translational modification of XDH. XDH requires the presence of the cofactor 
nicotinamide adenine dinucleotide (NAD+) as its primary electron acceptor, yet XOD 
is unable to bind to NAD+ and uses molecular oxygen (O2) as its electron acceptor 
(Vorbach et al., 2003). In both forms, xanthine oxidoreductase has a key role in 
purine catabolism by catalyzing two-steps of sequential oxidative hydroxylation from 
hypoxanthine to xanthine and from xanthine to the end product of the humans' purine 
metabolism called uric acid (Fukunari et al., 2004).  
 
1.3.4 Uric acid 
Uric acid (2,6,8-trihydroxypurine, C5H4N4O3) is the end product of purine catabolism 
in humans due to the loss of the uricase resulted from the various mutations of its 
gene as a consequence of the hominoids evolution occurred during the Miocene 
epoch (approximately 8-20 million years ago). This evolution may of importance to 
allow early hominoid ancestors survive with the food shortage and climate changes 
that occurred during the mid Miocene (Johnson et al., 2005; Johnson et al., 2011). As 
a consequence, humans have circulating uric acid levels that are five to twenty folds 
higher than most other mammals (Bobulescu and Moe, 2012). Normal uric acid 
range in human is between 3 and 7 mg/dL (Johnson et al., 2013). Therefore, the lack 
of uricase is the main reason that humans develop hyperuricemia and eventually gout 
(Álvarez-Lario and Macarrón-Vicente, 2010). 
 
1.3.5 Degradation of uric acid 
Uric acid is an intermediary product in most mammals with uricase (Kahn et al., 
1997). A complete chain of uricolytic or purinolytic enzymes namely uricase, 
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allantoinase, allantoicase, and urease is necessary for degrading purines completely 
(Florkin, 1949; Greene, 1954). The end product of purine degradation or uricolysis 
varies from species to species depending on the uricolytic enzyme(s) involved 
(Florkin, 1949 in Noguchi et al., 1979; Kahn et al., 1997). The enzyme uricase plays 
an important role in the degradation of uric acid by converting a water-insoluble uric 
acid to a highly water-soluble product called allantoin which is readily eliminated in 
the urine (Kahn et al., 1997). Allantoinase will then hydrolyzes allantoin to allantoic 
acid (Florkin, 1949; Greene, 1954; Kuzhivelil and Mohamed, 1998; Osuji and Ory, 
1986). Allantoic acid formed is the substrate for enzyme allantoicase to form urea 
and glyoxylic acid. Enzyme urease will then hydrolyzes urea to carbon dioxide (CO2) 
and ammonia (NH3) (Figure 1.3) (Florkin, 1949; Greene, 1954; Keilin, 1958 in 
Usuda et al., 1994). 
 
 
Figure 1.3: Uric acid degradation pathway (Florkin, 1949). 
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1.3.6 Excretion of uric acid 
Since humans lack the enzyme uricase, when in excess, uric acids are either 
consumed by other pathways or excreted via the kidney and gastrointestinal tract 
(Cannella and Mikuls, 2005). Gastrointestinal tract is responsible for one-third of the 
uric acid excretion. The remainder is handled primarily by the kidney which removes 
uric acid from the blood plasma into urine following a system that includes four 
components namely glomerular filtration, proximal tubular pre-secretory 
reabsorption, secretion, and post-secretory reabsorption (Prospert et al., 1993; Barr, 
1990).  
 
 Glomerular filtration is the first step in the complex process of uric acid 
excretion (Holechek, 2003). Approximately 95 % of the uric acid is filtered by the 
glomerular filtration barrier and subsequently undergoes bidirectional movement in 
the proximal tubule to enter the second step which involves pre-secretory 
reabsorption at the pre-secretory site (S1 segment of the proximal tubule), whereby 
approximately 99 % of the uric acid is reabsorbed. During the third step, secretion 
occurs at the tubulare (S2 segment of the proximal tubule) and approximately 50 % 
of the uric acid is secreted, followed by the post-secretory reabsorption that takes 
place at the post-secretory site (S3 segment of the proximal tubule), leading to 
approximately 40-50 % of the secreted uric acid being reabsorbed (Cannella and 
Mikuls, 2005; Diamond and Paolino, 1973; Ngo and Assimos, 2007; Prospert et al., 
1993). Eventually, the uric acid excreted in the urine accounts for approximately 5-
10 % of the glomerular filtrate (Gutman and Yu, 1958). Failure of any of these 
components could result in the development of hyperuricemia (Barr, 1990). 
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1.4 The etiology of hyperuricemia 
Defects in the de novo synthesis pathway, salvage pathway, and degradation and 
excretion of purines and uric acid may result in hyperuricemia, due mainly to the 
overproduction or underexcretion of uric acid or a combination of the two 
mechanisms (Dincer et al., 2002; Ghei et al., 2002; Barr, 1990).  
 
1.4.1 Uric acid overproduction 
The causes that affect the balance between uric acid production and elimination, 
leading to hyperuricemia, are multifactorial and include both genetic and 
environmental factors (den Boer, 2012). Overproduction of uric acid is often 
associated with abnormalities of the enzyme involved in the purine biosynthesis 
pathway. These include structural mutants of phosphoribosyl-pyrophosphate (PRPP) 
synthetase with increased activities, structural mutants of hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) with reduced activities, structural mutants of 
adenine phophoribosyltransferase (APRT) with reduced activities, and structural 
mutants of XOR with hyperactivities (Perez-Ruiz and Herrero-Beites, 2014; 
Sorensen, 2012; Wyngaarden, 1974).   
 
 There are a number of drugs that may cause hyperuricemia by stimulating 
uric acid production. Examples include fructose, xylitol, and theophylline which 
increase uric acid concentration in the blood by accelerating purine nucleotide 
degradation. In addition, certain cytotoxic agents such as anthracyclines and 
doxorubicin derivatives may also increase uric acid production by increasing the 
turnover rate of cell death (Moriwaki, 2014). 
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 Approximately two-thirds of the total body uric acid is produced 
endogenously, whilst the remaining one-third is accounted for by diet which serves 
as an exogenous source of the purine nucleotides (Schumacher, 2008). Therefore, 
dietary habit like high consumption of ethanol and protein-, fructose- and purine-rich 
foods such as red meats, organ meats, shellfish, anchovies, and sugared soft drinks 
are important factors that increase uric acid production (Keith and Gilliland, 2007; 
Terkeltaub et al., 2009; Villegas et al., 2012).   
 
1.4.2 Uric acid underexcretion 
In year 2003, Turner et al. showed that uromodulin mutation is one of the metabolic 
defects, leading to hyperuricemia due to uric acid underexcretion. Later, Zivna et al. 
(2009) reported that deletion or amino acid exchange mutations of a single leucine 
residue in the signal sequence of renin reduced the expression of renin and other 
components of the renin-angiotensin system and altered the juxtaglomerular 
apparatus functionality, leading to nephron dropout and progressive kidney failure 
and thus uric acid retention. In addition, the deficiency of G6Pase were not only 
reported to cause uric acid overproduction, they were also a cause for uric acid 
underexcretion as the degradation of the phosphorylated sugars accumulated due to 
GTPase mutants leads to the formation of lactate which may compete with uric acid 
for renal excretion (Cohen et al., 1985).   
 
 The use of certain medications may also causes uric acid retention and thus 
hyperuricemia. Examples include pyrazinamide (Cullen et al., 1956 in Yu, 1974), 
ethambutol (Postlethwaite et al., 1972 in Yu, 1974), thiazide and loop diuretics such 
as furosemide and bumetanide (Jutabha et al., 2010; Scott and Higgens, 1992), 
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cyclosporine (Gores et al., 1988), levadopa (Honda and Gindin, 1972 in Yu, 1974), 
nicotinic acid or niacin, cytotoxic agents, and low dose aspirin (Moriwaki, 2014; 
Vázquez-Mellado, 2004). 
 
 In addition, uric acid underexcretion may be caused by disease states such as 
renal insufficiency as 70 % of the uric acid is excreted from the kidney (Ohno, 2011). 
Therefore, hyperuricemia is common in renal allograft recipients because their renal 
function and hence the excretion of uric acid are compromised by 
immunosuppressive drugs and diuretics. Since immunosuppressive drugs such as 
cyclosporine were used to prevent rejection of the transplantation while diuretics 
such as thiazide and loop were used to control hypertension and edema in renal 
transplant recipients (Clive, 2000; Gores et al., 1988).   
 
 The consumption of alcoholic beverages causes not only uric acid 
overproduction but also uric acid underexcretion since alcohol catabolism increases 
the production of lactate, which is an antiuricosuric agent (Fallen and Fox, 1982). 
 
1.5 Prevalence of hyperuricemia  
Hyperuricemia is a health concern with worldwide distribution, reportedly afflicting 
5 to 30 % of the general population (Vázquez-Mellado et al., 2004). For instance, the 
prevalence of hyperuricemia in Japan was 24.4 % during year 1997-2000 (Nagahama 
et al., 2004). In Thailand, the overall prevalence of hyperuricemia was 10.6 % in 
year 1999-2000 (Lohsoonthorn et al., 2006). In Northern and Northeastern Chinese 
provinces, the prevalence of hyperuricemia was 13.7 % during year 2008-2010 (Qiu 
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et al., 2013). In Malaysia, 21.1 % of the population had rheumatic complaint during 
year 2007 (Veerapen et al., 2007). 
 
 The prevalence of hyperuricemia varies with race, gender, and age, and 
appears to be increasing worldwide (Singh et al., 2010; Vázquez-Mellado et al., 
2004). A higher incidence of hyperuricemia is observed in African Americans likely 
due to their greater risk of hypertension (Hochberg et al., 1995), and among Filipinos, 
Maori, Samoans, and other South Pacific Islanders probably due to their genetic and 
dietary factors that heighten predisposition (Harris, 2013). The occurrence of 
hyperuricemia is higher in men than in women with a reported men to women ratio 
ranged from 7:1 to 9:1. However, the ratio tends to equalize with increasing age 
since the serum uric acid level increases in women post-menopause. Therefore, the 
ratios of 4:1 and 3:1 were reported for those below and above the age of 65 years old, 
respectively (Doherty, 2009; Kramer and Curhan, 2002; Singh et al., 2010; Wallace 
et al., 2004). The likelihood of developing hyperuricemia increases with age, 
especially over 65 years old (Wallace et al., 2004).  
 
 The US National Health and Nutrition Examination Survey (NHANES) 
conducted during year 2007-2008 revealed that hyperuricemia affected 21.4 % or 
43.3 million individuals among adults in United States of America. The survey also 
showed that the prevalence of hyperuricemia has increased by 3.2 % compared to 
hyperuricemia prevalence of 18.2 % or 30.5 million recorded in the NHANES-III 
conducted during year 1988-1994. This signified that the prevalence of the 
hyperuricemia has been substantially sustained over the past decades and indeed may 
still be increasing (Rho et al., 2011; Zhu et al., 2011). 
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1.6 Co-morbidities of hyperuricemia  
Hyperuricemia is a known major risk factor for gout. It is also highly associated with, 
and may predispose to diseases as listed in the Table 1.4.  
 
 Table 1.4: Co-morbidities of hyperuricemia. 
Co-morbidities References  
 cancer and malignancy Fini et al., 2012 
  
 contrast-induced acute kidney injury Liu et al., 2013 
  
 coronory, cerebral and peripheral 
arterial disease 
Newland, 1975 
  
 diuresis Scott and Higgens, 1992 
  
 human immunodeficiency virus 
infection 
Manfredi et al., 1996 
Medina-Rodriguez et al., 1993 
Patel et al., 2013 
Walker et al., 2006 
  
 hypercholesterolemia Harris-Jones et al., 1956 
Marinoff et al., 1962 
Schoenfeld and Goldberger, 1963 cited 
in Fessel, 1972 
  
 hypertriglyceridemia Berkowitz, 1964 
  
 hyperparathyroidism Mintz et al., 1961 
  
 hyperthyroidism Sato et al., 1995 
  
 hypoglycemia and hyperglucagonemia Cohen et al., 1985 
  
 hypoparathyroidism Kirschner, 1956 cited in Yu, 1974 
  
 hypothyroidism Leeper et al., 1960 
  
 laxative abuse syndrome  Adam and Goebel, 1998 
Gupta and Kavanaugh-Danelon, 1989 
  
 lithiasis Kramer et al., 2003 
Kramer and Curhan, 2002 
Vázquez-Mellado, 2004 
 
